Key result
Management of type 2 diabetes in acute coronary syndromes increasingly incorporates novel therapies like SGLT2 inhibitors and GLP-1 receptor agonists alongside traditional insulin.
This article reviews the current state and future perspectives of managing type 2 diabetes in patients with acute coronary syndromes.
Answers are grounded in this paper and cite their sources.
Prompts guideline updates for T2DM in ACS; extends SGLT2i/GLP-1RA benefits to acute settings.
Keywords: Diabetes, acute coronary syndrome, acute myocardial infarction, insulin, SGLT2 inhibitors, GLP-1 receptor agonists.
No takes yet. Share an insight, caveat, or question.
Kotsa et al. (2023) studied this question. Management of type 2 diabetes in acute coronary syndromes increasingly incorporates novel therapies like SGLT2 inhibitors and GLP-1 receptor agonists alongside traditional insulin.
Synapse has enriched 10 related papers. Consider them for comparative context: